New hope against a deadly parasite: LXE408 trial shows promise
NCT ID NCT05957978
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called LXE408 in 52 adults with visceral leishmaniasis, a serious parasitic disease. The goal was to see if LXE408 could cure the infection by Day 28 compared to the standard treatment. The trial took place in Ethiopia and measured safety, drug levels, and how well the drug worked.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY VISCERAL LEISHMANIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Gondar
Gonder, Ethiopia